MedPath

An Open-label Pharmacokinetic Study of TS-172 in Patients on Hemodialysis

Phase 1
Completed
Conditions
Patients on Hemodialysis
Interventions
Registration Number
NCT06849778
Lead Sponsor
Taisho Pharmaceutical Co., Ltd.
Brief Summary

A phase 1, open-label, pharmacokinetic study of TS-172 in patients on hemodialysis

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
7
Inclusion Criteria
  1. Japanese male patients (outpatients) with chronic kidney disease receiving hemodialysis (HD or HDF) 3 times a week for at least 12 weeks prior to the screening test
  2. Patients aged >= 18 and < 75 years at the time of obtaining informed consent
Exclusion Criteria
  1. Patients with gastric or intestinal ulceration or a history of them within the past year prior to the date of initiation of treatment, or patients with inflammatory bowel disease or irritable bowel syndrome, or a history of these within the past 5 years prior to the date of initiation of treatment
  2. Patients scheduled for renal transplantation, home hemodialysis or change of dialysis facility (transfer or temporary dialysis at other hospital) during the study period
  3. Patients who frequently experience diarrhea (defined as Bristol Stool Scale score of 6 or higher)

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
TS-172TS-172-
Primary Outcome Measures
NameTimeMethod
Concentration of unchanged form in plasmaDay 1, 2, 8 and 9
Concentration of major metabolites in plasmaDay 1, 2, 8 and 9
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Taisho Pharmaceutical Co., Ltd selected site

🇯🇵

Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath